According to IMARC Group latest report titled “Biopharmaceutical Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on biopharmaceutical market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global biopharmaceutical market size reached US$ 273.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 480.0 Billion by 2028, exhibiting a growth rate (CAGR) of 10.1% during 2023-2028.
Biopharmaceuticals are a type of pharmaceutical drug that is created using living cells and are used to treat a wide variety of diseases. It is generally utilized to treat chronic and complex diseases, such as cancer, HIV/AIDS, Alzheimer’s, and autoimmune diseases. It is also used in the development of numerous types of vaccines, gene therapy, and regenerative medicine. It is produced by manipulating and exploiting the natural biological processes of living organisms. This involves the use of recombinant DNA technology, which is the process of combining genetic material from two different species to create a new organism. By doing this, scientists modify existing proteins or create new ones that allow them to create biopharmaceuticals with specific properties or effects.
Get a Free Sample Copy of this Report: https://www.imarcgroup.com/biotechnology-industry/requestsample
Market Trends:
The escalating demand for improved treatments majorly drives the global market. This can be supported by the increasing prevalence of chronic diseases due to excessive consumption of tobacco and alcohol, inadequate nutrition, and lack of physical activity. Along with this, the growing adoption of biopharmaceuticals, such as immunosera, hormones, cytokines, enzymes, and monoclonal antibodies, to treat rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases is contributing to the growth of the market. In addition, the rising utilization of cell and gene-based biopharmaceuticals to treat conditions without a cure is significantly supporting the demand. This is encouraging biopharmaceutical companies to develop more effective, safer, and faster-acting biopharmaceutical drugs, which are acting as another growth-inducing factor. Furthermore, the continuous advancements in biopharmaceuticals develop personalized treatments tailored to each patient’s specific needs while improving the effectiveness of treatments and reducing the risk of adverse side effects, creating a positive market outlook.
One of the key drivers of growth in the biopharmaceutical market is the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. These conditions are responsible for a significant proportion of the global disease burden and have led to an increased demand for effective treatments.
Another factor driving growth in this market is the increasing adoption of personalized medicine. Personalized medicine involves tailoring medical treatment to the individual characteristics of the patient, such as their genetic makeup. This approach is expected to lead to more effective and efficient treatments, and is therefore gaining traction in the biopharmaceutical market.
In conclusion, the biopharmaceutical market is a rapidly growing and evolving industry that is expected to continue to grow in the coming years. The increasing prevalence of chronic diseases and the adoption of personalized medicine are expected to be key drivers of growth in this market. Biologics, biosimilars, and CMOs are important segments of the biopharmaceutical market, and competition is expected to remain high among both large and small companies.
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- AbbVie Inc.
- Amgen Inc
- Biogen Inc.
- Eli Lilly and Company
- Hoffmann-La Roche AG
- Johnson & Johnson
- Merck & Co. Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A
Biopharmaceutical Market Segmentation:
Our report has categorized the market based on regions, indication and class.
Breakup by Indication:
- Autoimmune diseases
- Oncology
- Metabolic disorders
- Others
Breakup by Class:
- Recombinant Proteins
- Monoclonal Antibodies
- Purified Proteins
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
